Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
287 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Addiction - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Addiction - Pipeline Review, H1 2015’, provides an overview of the Addiction’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Addiction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Addiction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Addiction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Addiction Overview 11 Therapeutics Development 12 Pipeline Products for Addiction - Overview 12 Pipeline Products for Addiction - Comparative Analysis 13 Addiction - Therapeutics under Development by Companies 14 Addiction - Therapeutics under Investigation by Universities/Institutes 20 Addiction - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Addiction - Products under Development by Companies 26 Addiction - Products under Investigation by Universities/Institutes 33 Addiction - Companies Involved in Therapeutics Development 35 AbbVie Inc. 35 Acura Pharmaceuticals, Inc. 36 Addex Therapeutics Ltd 37 Adial Pharmaceuticals, LLC 38 Alkermes Plc 39 Aphios Corporation 40 Aradigm Corporation 41 Arena Pharmaceuticals, Inc. 42 Astraea Therapeutics, LLC 43 AstraZeneca PLC 44 Beech Tree Labs, Inc. 45 BioDelivery Sciences International, Inc. 46 Bionex Pharmaceuticals LLC 47 Bioprojet SCR 48 Camurus AB 49 Celtic Pharmaceutical Holdings L.P. 50 Cerecor Inc. 51 Curemark, LLC 52 D&A Pharma SAS 53 Eli Lilly and Company 54 Embera NeuroTherapeutics, Inc. 55 Euthymics Bioscience, Inc. 56 Foresee Pharmaceuticals, LLC 57 FORUM Pharmaceuticals Inc. 58 Gilead Sciences, Inc. 59 GlaxoSmithKline plc 60 Grunenthal GmbH 61 Heptares Therapeutics Ltd. 62 Immunovaccine, Inc. 63 Indivior PLC 64 INSYS Therapeutics, Inc. 65 Invion Limited 66 Johnson & Johnson 67 Kyorin Pharmaceutical Co., Ltd. 68 Lightlake Therapeutics Inc. 69 Lohocla Research Corporation 70 MAKScientific, LLC 71 NAL Pharmaceuticals Ltd. 72 Nanotherapeutics, Inc. 73 Omeros Corporation 74 Pfizer Inc. 75 Relmada Therapeutics, Inc. 76 Rottapharm SpA 77 Royalty Pharma 78 Selecta Biosciences, Inc. 79 SK Biopharmaceuticals Co., Ltd. 80 Sun Pharma Advanced Research Company Ltd. 81 Targacept, Inc. 82 Tekmira Pharmaceuticals Corp. 83 Teva Pharmaceutical Industries Limited 84 Titan Pharmaceuticals, Inc. 85 Tonix Pharmaceuticals Holding Corp. 86 VM Discovery, Inc. 87 Zynerba Pharmaceuticals, Inc. 88 Addiction - Therapeutics Assessment 89 Assessment by Monotherapy Products 89 Assessment by Combination Products 90 Assessment by Target 91 Assessment by Mechanism of Action 94 Assessment by Route of Administration 97 Assessment by Molecule Type 99 Drug Profiles 101 (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 101 (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 102 (disulfiram + selegiline) - Drug Profile 103 (oxazepam + metyrapone) - Drug Profile 104 (topiramate + ondansetron hydrochloride) - Drug Profile 106 ABT-436 - Drug Profile 107 ADX-71441 - Drug Profile 108 ADX-88178 - Drug Profile 109 AM-6527 - Drug Profile 110 amitifadine - Drug Profile 112 Anatabine - Drug Profile 114 Antisense Gene Therapy to Inhibit Aldehyde Dehydrogenase for Alcoholism - Drug Profile 115 arbaclofen placarbil - Drug Profile 116 ARD-1600 - Drug Profile 118 ASB - Drug Profile 119 AT-1001 - Drug Profile 120 baclofen ER - Drug Profile 121 BP-1.4979 - Drug Profile 122 BTL-ng - Drug Profile 123 Buprenorphine Hemiadipate Hydrochloride - Drug Profile 124 buprenorphine hydrochloride - Drug Profile 125 buprenorphine hydrochloride - Drug Profile 126 buprenorphine hydrochloride - Drug Profile 127 buprenorphine hydrochloride depot - Drug Profile 130 buprenorphine hydrochloride ER - Drug Profile 131 buprenorphine hydrochloride SR - Drug Profile 132 cannabidiol - Drug Profile 134 cannabidiol - Drug Profile 135 cannabidiol - Drug Profile 137 carisbamate - Drug Profile 138 CM-1212 - Drug Profile 140 CR-5542 Series - Drug Profile 141 CR-5772 Series - Drug Profile 142 dipraglurant IR - Drug Profile 143 dronabinol - Drug Profile 144 Drug for Dependence - Drug Profile 145 Drug to Inhibit Triple Reuptake for Alcohol Dependence - Drug Profile 146 Drugs to Activate HAT for CNS Disorders - Drug Profile 147 Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 148 Drugs to Inhibit Histone Deacetylase for CNS Disorders - Drug Profile 149 Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 150 encenicline hydrochloride - Drug Profile 151 FP-004 - Drug Profile 154 FP-007 - Drug Profile 155 GET-73 - Drug Profile 156 GS-6637 - Drug Profile 157 GSK-598809 - Drug Profile 158 ibudilast - Drug Profile 159 JNJ-31020028 - Drug Profile 161 JNJ-5234801 - Drug Profile 162 lorcaserin hydrochloride - Drug Profile 163 LT-22 - Drug Profile 166 LY-2456302 - Drug Profile 167 LY-2940094 - Drug Profile 168 MAL - Drug Profile 169 methadone IR - Drug Profile 170 methoxycoronaridine - Drug Profile 171 nadolol - Drug Profile 172 naltrexone - Drug Profile 174 naltrexone - Drug Profile 175 NIC7-DT - Drug Profile 176 nicotine - Drug Profile 177 nicotine - Drug Profile 178 Nicotine Vaccine - Drug Profile 179 NOX-B11 - Drug Profile 180 odelepran hydrochloride - Drug Profile 181 OMS-405 - Drug Profile 182 OMS-527 - Drug Profile 183 ondansetron hydrochloride - Drug Profile 185 PF-04457845 - Drug Profile 186 PF-05402536 - Drug Profile 187 PF-06413367 - Drug Profile 188 PF-5006739 - Drug Profile 189 phantasmidine - Drug Profile 190 RO-656570 - Drug Profile 191 samidorphan - Drug Profile 192 saracatinib difumarate - Drug Profile 193 SEL-068 - Drug Profile 195 SLV-330 - Drug Profile 197 Small Molecule for Central Nervous System - Drug Profile 198 Small Molecule for Drug Addiction - Drug Profile 200 Small Molecule for Smoking Cessation - Drug Profile 201 Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile 202 Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile 203 Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 204 Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 205 Small Molecule to Antagonize Ghrelin for Alcoholism - Drug Profile 206 Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile 207 Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Drug Profile 208 Small Molecule to Inhibit BRD for Cocaine Dependence - Drug Profile 209 Small Molecule to Inhibit Kappa Opioid Receptor for CNS - Drug Profile 210 Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Drug Profile 211 Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 212 Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 213 Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 214 Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 215 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 216 Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 217 Small Molecules to Inhibit NTR1 for Psychiatric Disorders - Drug Profile 218 Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders - Drug Profile 219 sodium oxybate IR - Drug Profile 220 Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile 221 Synthetic Peptides to Target DOR, MOR and MRP-1 for Oncology and CNS Disorders - Drug Profile 222 TA-CD - Drug Profile 223 TKM-ALDH2 - Drug Profile 224 TV-1380 - Drug Profile 225 Vaccine for Cocaine Addiction - Drug Profile 226 Vaccine for Cocaine Addiction - Drug Profile 227 Vaccine for Methamphetamine Addiction - Drug Profile 228 Vaccine for Nicotine Addiction - Drug Profile 229 Vaccine for Nicotine Addiction - Drug Profile 230 Vaccine for Opium Addiction - Drug Profile 231 VMD-2202 - Drug Profile 232 Addiction - Recent Pipeline Updates 233 Addiction - Dormant Projects 261 Addiction - Discontinued Products 268 Addiction - Product Development Milestones 270 Featured News & Press Releases 270 Appendix 278 Methodology 278 Coverage 278 Secondary Research 278 Primary Research 278 Expert Panel Validation 278 Contact Us 278 Disclaimer 279
List of Tables Number of Products under Development for Addiction, H1 2015 20 Number of Products under Development for Addiction - Comparative Analysis, H1 2015 21 Number of Products under Development by Companies, H1 2015 23 Number of Products under Development by Companies, H1 2015 (Contd..1) 24 Number of Products under Development by Companies, H1 2015 (Contd..2) 25 Number of Products under Development by Companies, H1 2015 (Contd..3) 26 Number of Products under Development by Companies, H1 2015 (Contd..4) 27 Number of Products under Investigation by Universities/Institutes, H1 2015 29 Comparative Analysis by Late Stage Development, H1 2015 30 Comparative Analysis by Clinical Stage Development, H1 2015 31 Comparative Analysis by Early Stage Development, H1 2015 32 Comparative Analysis by Unknown Stage Development, H1 2015 33 Products under Development by Companies, H1 2015 34 Products under Development by Companies, H1 2015 (Contd..1) 35 Products under Development by Companies, H1 2015 (Contd..2) 36 Products under Development by Companies, H1 2015 (Contd..3) 37 Products under Development by Companies, H1 2015 (Contd..4) 38 Products under Development by Companies, H1 2015 (Contd..5) 39 Products under Development by Companies, H1 2015 (Contd..6) 40 Products under Investigation by Universities/Institutes, H1 2015 41 Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 42 Addiction - Pipeline by AbbVie Inc., H1 2015 43 Addiction - Pipeline by Acura Pharmaceuticals, Inc., H1 2015 44 Addiction - Pipeline by Addex Therapeutics Ltd, H1 2015 45 Addiction - Pipeline by Adial Pharmaceuticals, LLC, H1 2015 46 Addiction - Pipeline by Alkermes Plc, H1 2015 47 Addiction - Pipeline by Aphios Corporation, H1 2015 48 Addiction - Pipeline by Aradigm Corporation, H1 2015 49 Addiction - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 50 Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2015 51 Addiction - Pipeline by AstraZeneca PLC, H1 2015 52 Addiction - Pipeline by Beech Tree Labs, Inc., H1 2015 53 Addiction - Pipeline by BioDelivery Sciences International, Inc., H1 2015 54 Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2015 55 Addiction - Pipeline by Bioprojet SCR, H1 2015 56 Addiction - Pipeline by Camurus AB, H1 2015 57 Addiction - Pipeline by Celtic Pharmaceutical Holdings L.P., H1 2015 58 Addiction - Pipeline by Cerecor Inc., H1 2015 59 Addiction - Pipeline by Curemark, LLC, H1 2015 60 Addiction - Pipeline by D&A Pharma SAS, H1 2015 61 Addiction - Pipeline by Eli Lilly and Company, H1 2015 62 Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 63 Addiction - Pipeline by Euthymics Bioscience, Inc., H1 2015 64 Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 65 Addiction - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 66 Addiction - Pipeline by Gilead Sciences, Inc., H1 2015 67 Addiction - Pipeline by GlaxoSmithKline plc, H1 2015 68 Addiction - Pipeline by Grunenthal GmbH, H1 2015 69 Addiction - Pipeline by Heptares Therapeutics Ltd., H1 2015 70 Addiction - Pipeline by Immunovaccine, Inc., H1 2015 71 Addiction - Pipeline by Indivior PLC, H1 2015 72 Addiction - Pipeline by INSYS Therapeutics, Inc., H1 2015 73 Addiction - Pipeline by Invion Limited, H1 2015 74 Addiction - Pipeline by Johnson & Johnson, H1 2015 75 Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 76 Addiction - Pipeline by Lightlake Therapeutics Inc., H1 2015 77 Addiction - Pipeline by Lohocla Research Corporation, H1 2015 78 Addiction - Pipeline by MAKScientific, LLC, H1 2015 79 Addiction - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 80 Addiction - Pipeline by Nanotherapeutics, Inc., H1 2015 81 Addiction - Pipeline by Omeros Corporation, H1 2015 82 Addiction - Pipeline by Pfizer Inc., H1 2015 83 Addiction - Pipeline by Relmada Therapeutics, Inc., H1 2015 84 Addiction - Pipeline by Rottapharm SpA, H1 2015 85 Addiction - Pipeline by Royalty Pharma, H1 2015 86 Addiction - Pipeline by Selecta Biosciences, Inc., H1 2015 87 Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 88 Addiction - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 89 Addiction - Pipeline by Targacept, Inc., H1 2015 90 Addiction - Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 91 Addiction - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 92 Addiction - Pipeline by Titan Pharmaceuticals, Inc., H1 2015 93 Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 94 Addiction - Pipeline by VM Discovery, Inc., H1 2015 95 Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 96 Assessment by Monotherapy Products, H1 2015 97 Assessment by Combination Products, H1 2015 98 Number of Products by Stage and Target, H1 2015 100 Number of Products by Stage and Mechanism of Action, H1 2015 103 Number of Products by Stage and Route of Administration, H1 2015 106 Number of Products by Stage and Molecule Type, H1 2015 108 Addiction Therapeutics - Recent Pipeline Updates, H1 2015 241 Addiction - Dormant Projects, H1 2015 269 Addiction - Dormant Projects (Contd..1), H1 2015 270 Addiction - Dormant Projects (Contd..2), H1 2015 271 Addiction - Dormant Projects (Contd..3), H1 2015 272 Addiction - Dormant Projects (Contd..4), H1 2015 273 Addiction - Dormant Projects (Contd..5), H1 2015 274 Addiction - Dormant Projects (Contd..6), H1 2015 275 Addiction - Discontinued Products, H1 2015 276 Addiction - Discontinued Products (Contd..1), H1 2015 277
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
